The United States market has experienced a 2.1% increase over the past week and is up 14% over the last year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Super Micro Computer |
24.71% |
39.09% |
★★★★★★ |
|
Circle Internet Group |
32.27% |
61.44% |
★★★★★★ |
|
Mereo BioPharma Group |
50.84% |
58.22% |
★★★★★★ |
|
Ardelyx |
21.02% |
61.29% |
★★★★★★ |
|
TG Therapeutics |
26.46% |
38.75% |
★★★★★★ |
|
AVITA Medical |
27.42% |
61.04% |
★★★★★★ |
|
Alkami Technology |
20.53% |
76.67% |
★★★★★★ |
|
Alnylam Pharmaceuticals |
23.72% |
59.95% |
★★★★★★ |
|
Ascendis Pharma |
35.07% |
59.92% |
★★★★★★ |
|
Lumentum Holdings |
23.02% |
103.97% |
★★★★★★ |
Click here to see the full list of 217 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Amicus Therapeutics, Inc. is a biotechnology company dedicated to discovering, developing, and delivering novel medicines for rare diseases globally, with a market capitalization of approximately $1.88 billion.
Operations: FOLD focuses on the discovery, development, and commercialization of advanced therapies for rare diseases, generating $543.14 million in revenue.
Amicus Therapeutics, despite being unprofitable, shows promising growth prospects with a revenue increase forecasted at 17.7% annually, outpacing the US market’s 8.7%. The company’s recent approval in Japan for its innovative two-component therapy for Pompe disease underscores its commitment to expanding global access to treatment. This strategic move, coupled with a significant reduction in net loss from $48.42 million to $21.69 million year-over-year and an anticipated profitability within three years, positions Amicus as a potential key player in biotech innovation and market expansion.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Okta, Inc. operates as an identity partner both in the United States and internationally, with a market cap of $17.35 billion.
Operations: Okta generates revenue primarily from its Internet Software & Services segment, amounting to $2.68 billion.
Okta, recently profitable, is navigating the high-growth tech landscape with innovations like its Cross App Access protocol, enhancing AI agent security across enterprise applications. This move reflects a strategic pivot to address the complexities of modern cybersecurity, especially as enterprises integrate more autonomous AI tools. With a robust 25% expected annual earnings growth and recent revenue hitting $688 million—a significant leap from last year—the company is poised for continued expansion. These developments come alongside Okta’s active participation in major industry conferences, underscoring its commitment to shaping future tech standards and practices.
